About 1.2 mg of compound 1, 1.0 mg of compound 2, and 0.6 mg of compound 3 were isolated.
METHODS: Subjects were randomized to use of a placebo (n=82), 5 mg of tadalafil (n=85), or 50 mg of sildenafil (n=77) daily for 6 months.
Typically, 172 mg of FAI, 461 mg of PbI2 and 99 mg of NMP were added to 600 mg of DMF.
With 2 mol% of Cs, the precursor solution was prepared by mixing 163.0 mg of FAI, 8.2 mg of PEAI, 5.0 mg of CsI (Alfa Aesar, 99.999%), 453.4 mg of PbI2 and 97.4 mg of NMP in 600 mg.
For example, FAPbI3 with 1.67 mol% PEA2PbI4 PVSK was formed from the precursor solution containing 166.4 mg of FAI, 8.2 mg of phenylethylammonium iodide (PEAI), 453.4 mg of PbI2 and 97.4 mg of NMP in 600 mg of DMF.
Apparent kinetic parameters were determined with 0.05 mg of DtHNL1 (final concentration 0.1 mg/mL).
In total, 240.8 mg of FAI, 646.8 mg of PbI2, and 18.2 mg of CsI were dissolved in 1 mL of DMF and DMSO (4:1, volume/volume), with stirring at 60 °C for 2 h.
Substrates were suspended facedown above ~15 mg of MoO3 (≥99.5% Sigma Aldrich) in a crucible placed downstream from a different crucible containing 80 mg of Sulfur (≥99.5% Sigma Aldrich).
Then, 61 mg of (1,2-13C2 glyoxylic acid (2 eq). was added, and the reaction was stirred at 50 °C for 3 h.
